JPRN-UMIN000005923Completed未知
Phase 1 comparative study of intravenous formulation of acetaminophen and oral formulation of acetaminophen - Phase 1 comparative study of intravenous formulation of acetaminophen and oral formulation of acetaminophen
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Terumo Corporation
- Enrollment
- 20
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- Male
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1) Subject who has been tested positive in a urine drug test or has a history of drug abuse. 2) Subject who has been tested positive for HBs antigen, HCV antibody or HIV antibody, or who has a positive serological test for syphilis. 3) Subject who has a history of hypersensitivity or allergy to the study drug (active component and additives) 4) Subject who currently has or has a history of peptic ulcer; or subject who currently has or has a history of asthma. 5) Subject with clinically significant disease related to the heart, liver, kidneys, respiratory system, gastrointestinal system, endocrine system, immune system, skin, blood, or psychiatric/nervous system. 6) Subject who has liver function test values (T-Bil/D-Bil, ALT (GPT), AST (GOT), gamma-GTP and ALP) that exceed the facility's upper limit. However, if the investigator deems that the reason for exceeding the limit is not due to the liver, the subject may be enrolled. 7) Subject who currently has or have a history of clinically significant bleeding or bleeding tendency. 8) Subject who has taken other medication or supplements within 1 week prior to study drug administration. 9) Subject who need to take other medication concurrently while participating in this study. 10) Subject who smoked tobacco within 1 month prior to study drug administration. 11) Subject who habitually consume a large amount of alcohol (ingestion of >=60 g per day as pure alcohol), or have ingested alcohol within 3 days prior to study drug administration. 12) Subject who has ingested food products containing St. John's wort within 2 weeks prior to study drug administration. 13) Subjects who has ingested grapefruit or processed grapefruit products within 1 week prior to study drug administration.
Investigators
Similar Trials
Recruiting
Phase 1
Phase 1 Hepatic Insufficiency Trial of Methoxyethyl Etomidate HydrochlorideHepatic InsufficiencyNCT06176716Ahon Pharmaceutical Co., Ltd.24
Terminated
Phase 1
Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.Relapsed or Refractory T-cell Acute Lymphoblastic LeukaemiaB-cell Precursor Acute Lymphoblastic LeukaemiaT-cell Non-Hodgkin's LymphomaNCT00742495Mundipharma Research Limited2
Recruiting
Phase 1
A Phase-I clinical study of intravenous AntiPlatelet, AntiCoagulant (APAC) in healthy subjects.CTRI/2023/04/051500Cadila Pharmaceutical Limited
Completed
Not Applicable
Comparison of effect of intravenous administration of Lidocaine-Fentanyl and lidocaine on reduction of propofol induced pain during intravenous injectioComplication of anaesthesia.Other complications of anaesthesiaIRCT2016051215281N9Vice chancellor for International branch of Shiraz Medical Sciences150
Suspended
Phase 1
Study With Heparin Sodium in Intravenous AdministrationHeparinNCT03125187União Química Farmacêutica Nacional S/A24